Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography
\[18F\]Florbetaben PET/CT imaging will noninvasively assess amyloid deposition in systemic amyloidosis.
Multiple Myeloma
DRUG: [18F]Florbetaben
sensitivity and specificity per patient analysis, Sensitivity and specificity of \[18F\]Florbetaben PET/CT for the diagnosis of subjects with clinical, laboratory, radiological, or histopathological evidence of amyloidosis, Up to 6 months after [18F]Florbetaben PET/CT scanning
sensitivity and specificity per organ analysis, Sensitivity and specificity of \[18F\]Florbetaben PET/CT for the diagnosis of affected organs with clinical, laboratory, radiological, or histopathological evidence of amyloidosis, Up to 6 months after [18F]Florbetaben PET/CT scanning|Correlation with severity, Correlation of \[18F\]Florbetaben activity with clinical/radiological/histopathological indices of amyloidosis severity, Up to 6 months after [18F]Florbetaben PET/CT scanning|Adverse events, Adverse events will be monitored., Up to 28 days after [18F]Florbetaben PET/CT scanning
Diagnostic validity of \[18F\]Florbetaben PET for detecting amyloidosis will be assessed in subjects with multiple myeloma.